

## Erratum to: Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

Christophe Massard · Jane Margetts · Nadia Amellal ·  
Yvette Drew · Ratislav Bahleda · Peter Stephens ·  
Jean Pierre Armand · Hilary Calvert · Jean Charles Soria ·  
Cinthya Coronado · Carmen Kahatt · Vicente Alfaro ·  
Mariano Siguero · Carlos Fernández-Teruel · Ruth Plummer

Published online: 21 April 2013  
© Springer Science+Business Media New York 2013

**Erratum to: Invest New Drugs**  
**DOI 10.1007/s10637-012-9843-5**

In the original version of the published article, Peter Stephens name was spelled incorrectly as Peter Stevens. The correct spelling is shown above.

---

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-012-9843-5>.

---

C. Massard (✉) · N. Amellal · R. Bahleda · J. P. Armand ·  
J. C. Soria  
SITEP (Service des Innovations Thérapeutiques Précoces),  
Institute Gustave Roussy, 114, rue Edouard Vaillant,  
94800 Villejuif, France  
e-mail: christophe.massard@igr.fr

J. Margetts · Y. Drew · P. Stephens · H. Calvert · R. Plummer  
Northern Centre for Cancer Care, Freeman Hospital,  
Newcastle Upon Tyne, UK

C. Coronado · C. Kahatt · V. Alfaro · M. Siguero ·  
C. Fernández-Teruel  
PharmaMar, Clinical R&D, Colmenar Viejo,  
Madrid, Spain